Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the cotext of Paclitaxel + Pembrolizumab & Breast Cancer / Mammacarcinoma (TNBC), paclitaxel + pembrolizumab is an FDA‑approved regimen for PD‑L1‑positive (CPS ≥10) metastatic/locally recurrent Breast Cancer / Mammacarcinoma (TNBC) in the first‑line setting (1, 2).
Paclitaxel + pembrolizumab is also an EMA‑approved regimen for PD‑L1‑positive (CPS ≥10) metastatic/locally recurrent Breast Cancer / Mammacarcinoma (TNBC) in the first‑line setting (3).
…